Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, montelukast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
80
States / cities
Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729
Conditions
Middle Ear Disease, Nasal Allergy
Interventions
ragweed, histamine, pseudoephedrine, Oxymetazoline
Biological · Drug
Lead sponsor
Cuneyt M. Alper
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Hemangioma
Interventions
topical timolol maleate, Pulsed dye laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 3 Months
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Treatment of Acute Sinusitis

NCT00377403
Conditions
Acute Respiratory Infections, Acute Rhinosinusitis
Interventions
Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alcohol Use
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Allergic Reactions
Interventions
Neffy, Adrenaline
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Glenview, Illinois + 3 more
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions

NCT04743362
Conditions
Skin Lesion, Mucosal Lesion
Interventions
Dermoscopic imaging, 3-dimensional total body photography, Confocal microscopy, Optical Coherence Tomography imaging, Ultrasound, Hyperspectral imaging, Electrical impedance spectroscopy, Patient self-imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
5,010 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
New York, New York
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effective Interventions to Overcome Severe Gag Reflex

NCT07099131
Conditions
Gagging
Interventions
Anesthetic spray, Acupuncture, Masking Tape
Drug · Device · Genetic
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mydriasis
Interventions
MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop
Combination Product · Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Artesia, California
Conditions
Stress Disorders, Post-Traumatic, Alcoholism
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682
Conditions
Posttraumatic Stress Disorder, Anxiety Disorder
Interventions
Propranolol, Reactivation, Mifepristone, Intranasal oxytocin
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Mydriasis
Interventions
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE)
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California